Literature DB >> 35692443

Tumorigenicity risk of iPSCs in vivo: nip it in the bud.

Chaoliang Zhong1, Miao Liu1, Xinghua Pan2, Haiying Zhu1.   

Abstract

In 2006, Takahashi and Yamanaka first created induced pluripotent stem cells from mouse fibroblasts via the retroviral introduction of genes encoding the transcription factors Oct3/4, Sox2, Klf44, and c-Myc. Since then, the future clinical application of somatic cell reprogramming technology has become an attractive research topic in the field of regenerative medicine. Of note, considerable interest has been placed in circumventing ethical issues linked to embryonic stem cell research. However, tumorigenicity, immunogenicity, and heterogeneity may hamper attempts to deploy this technology therapeutically. This review highlights the progress aimed at reducing induced pluripotent stem cells tumorigenicity risk and how to assess the safety of induced pluripotent stem cells cell therapy products.
© The Author(s) 2022. Published by Oxford University Press on behalf of the West China School of Medicine & West China Hospital of Sichuan University.

Entities:  

Keywords:  chemical-induced reprogramming; drug-inducible suicide system; induced pluripotent stem cells (iPSCs); regenerative medicine; reprogramming transcription factors; tumorigenicity

Year:  2022        PMID： 35692443      PMCID： PMC9026204          DOI： 10.1093/pcmedi/pbac004

Source DB:  PubMed          Journal:  Precis Clin Med        ISSN： 2516-1571


  107 in total

1.  c-Myc is dispensable for direct reprogramming of mouse fibroblasts.

Authors:  Marius Wernig; Alexander Meissner; John P Cassady; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2007-12-13       Impact factor: 24.633

Review 2.  Methods for making induced pluripotent stem cells: reprogramming à la carte.

Authors:  Federico González; Stéphanie Boué; Juan Carlos Izpisúa Belmonte
Journal:  Nat Rev Genet       Date:  2011-02-22       Impact factor: 53.242

Review 3.  Concise review: Genomic instability in human stem cells: current status and future challenges.

Authors:  Pedro H Oliveira; Cláudia Lobato da Silva; Joaquim M S Cabral
Journal:  Stem Cells       Date:  2014-11       Impact factor: 6.277

4.  Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency.

Authors:  Frederick Anokye-Danso; Chinmay M Trivedi; Denise Juhr; Mudit Gupta; Zheng Cui; Ying Tian; Yuzhen Zhang; Wenli Yang; Peter J Gruber; Jonathan A Epstein; Edward E Morrisey
Journal:  Cell Stem Cell       Date:  2011-04-08       Impact factor: 24.633

5.  Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation.

Authors:  Xiaoou Zhou; Swati Naik; Olga Dakhova; Gianpietro Dotti; Helen E Heslop; Malcolm K Brenner
Journal:  Mol Ther       Date:  2015-12-28       Impact factor: 11.454

6.  Efficient exogenous DNA-free reprogramming with suicide gene vectors.

Authors:  Minhyung Lee; Jeongmin Ha; Ye Seul Son; Hyunjun Ahn; Kwang Bo Jung; Mi-Young Son; Janghwan Kim
Journal:  Exp Mol Med       Date:  2019-07-19       Impact factor: 8.718

7.  Cellular reprogramming with multigene activation by the delivery of CRISPR/dCas9 ribonucleoproteins via magnetic peptide-imprinted chitosan nanoparticles.

Authors:  Mei-Hwa Lee; Cheng-Chih Lin; James L Thomas; Jin-An Li; Hung-Yin Lin
Journal:  Mater Today Bio       Date:  2021-01-20

8.  Efficient Genetic Safety Switches for Future Application of iPSC-Derived Cell Transplants.

Authors:  Julia Dahlke; Juliane W Schott; Philippe Vollmer Barbosa; Denise Klatt; Anton Selich; Nico Lachmann; Michael Morgan; Thomas Moritz; Axel Schambach
Journal:  J Pers Med       Date:  2021-06-17

9.  Dynamics of Telomere Rejuvenation during Chemical Induction to Pluripotent Stem Cells.

Authors:  Haifeng Fu; Cheng-Lei Tian; Xiaoying Ye; Xiaoyan Sheng; Hua Wang; Yifei Liu; Lin Liu
Journal:  Stem Cell Reports       Date:  2018-05-31       Impact factor: 7.765

10.  Polymeric Nanovectors Incorporated with Ganciclovir and HSV-tk Encoding Plasmid for Gene-Directed Enzyme Prodrug Therapy.

Authors:  Alicia J Sawdon; Jun Zhang; Sarah Peng; Esmael M Alyami; Ching-An Peng
Journal:  Molecules       Date:  2021-03-21       Impact factor: 4.411
View more
  1 in total

Review 1.  Strategies to Improve the Safety of iPSC-Derived β Cells for β Cell Replacement in Diabetes.

Authors:  Silvia Pellegrini; Valentina Zamarian; Valeria Sordi
Journal:  Transpl Int       Date:  2022-08-24       Impact factor: 3.842
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.